Hematology

Internal Medicine

Questions discussed in this category

Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?

When now would you consider regimens such as BV-AVD or BrECADD in advanced stage HL?

3 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-10-20

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

The New England journal of medicine, 2024 Oct 17

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Related Topics in Hematology